Mebendazole Suppresses Colorectal Tumors with Low PNLDC1 Levels, Preclinical Study Finds
Preclinical work links low PNLDC1 expression to aggressive colorectal cancer growth via TUBB4B — and shows the antiparasitic mebendazole, a TUBB4B inhibitor, suppressing that growth in cells, xenografts and patient-derived tumor clusters.
By Sanare Lab · September 24, 2026 · 1 min read
Key Takeaway
Colorectal tumors with low levels of the enzyme PNLDC1 grow more aggressively, and a new preclinical study shows the antiparasitic mebendazole — acting as a TUBB4B inhibitor — suppressing that excess growth in cancer cells, mouse xenografts and patient-derived tumor clusters. Bench evidence only; no patients were treated.
A team led by Lexin Liu reported in Exploration (September 21, 2026) that PNLDC1, a deadenylase enzyme sitting in the endoplasmic reticulum, is under-expressed in an analysis of 91 clinical colorectal cancer (CRC) tissue samples. Functional experiments identified PNLDC1 as a tumor suppressor: it binds cell-cycle–related mRNAs and drives the degradation of TUBB4B mRNA, a tubulin gene that fuels CRC proliferation when left unchecked. Restoring TUBB4B reversed PNLDC1's suppressive effect, marking the tubulin as the actionable node.
That is where mebendazole comes in: as a TUBB4B inhibitor, it effectively suppressed the enhanced proliferation of low-PNLDC1 tumors across all three model systems. The abstract reports no effect sizes (no IC50 or tumor-volume figures), so the magnitude of the benefit remains to be quantified — and PNLDC1 status would need to prove itself as a biomarker. This is mechanism-level evidence, not a clinical signal; for how benzimidazoles are actually being used and discussed, see our dosing calculator, the fenbendazole vs mebendazole comparison and the wider mebendazole mechanism research.
References
- Liu L, Guan Y, Qin Y, et al. ER-Localized Deadenylase PNLDC1 Suppresses Colorectal Cancer Progression by Targeting the mRNA Decay of TUBB4B. Exploration. 2026 Sep 21. doi:10.1002/exp2.70222. PMID: 42774471.
Medical Disclaimer
This article is for informational purposes only and is not medical advice. The study described is preclinical research in laboratory models, not a trial in patients. Never start, stop or change any medication without consulting a licensed healthcare provider.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.